Contact
searchSearch
HMP Global
Login

Debate: What is the Main Objective of Therapy in CML?: Improve Survival Endpoints

LL&M Great Debates 2020

Recent News

News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology
News
Real-World Analysis Evaluates Survival and Quality of Life Patterns of Third-Line Systemic Therapies for ES-SCLC
03/04/2026
Emily Estrada
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was associated with limited survival benefit and stability, but did not show improved quality of life, in a real-world registry analysis of treatment patterns for patients with extensive-stage small cell lung...
Third-line systemic therapy was...
03/04/2026
Oncology
News
Sequential Thoracic Radiotherapy After Chemoimmunotherapy Associated With Improved Survival in ES-SCLC
03/04/2026
Emily Estrada
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with extensive-stage small cell lung cancer responding to first-line chemoimmunotherapy, sequential thoracic radiotherapy was associated with improved progression-free and overall survival and fewer adverse events compared with...
Among patients with...
03/04/2026
Oncology
News
Real-World Analysis Identifies Clinical Predictors of Long-Term Response and Survival with Atezolizumab Plus Chemotherapy in ES-SCLC: CLINATEZO Study
03/03/2026
Emily Estrada
In a real-world ES-SCLC cohort treated with atezolizumab plus chemotherapy, long-term survival was achieved in a subset of patients, with former smoking status and performance status predicting durable response.
In a real-world ES-SCLC cohort treated with atezolizumab plus chemotherapy, long-term survival was achieved in a subset of patients, with former smoking status and performance status predicting durable response.
In a real-world ES-SCLC cohort...
03/03/2026
Oncology
News
Concurrent Radiotherapy With Tarlatamab Demonstrates Low Toxicity, Promising Disease Control in Extensive-Stage Small Cell Lung Cancer
03/03/2026
Emily Estrada
In patients with extensive-stage small cell lung cancer, concurrent radiotherapy during tarlatamab treatment was associated with low rates of severe toxicity and local tumor regression.
In patients with extensive-stage small cell lung cancer, concurrent radiotherapy during tarlatamab treatment was associated with low rates of severe toxicity and local tumor regression.
In patients with extensive-stage...
03/03/2026
Oncology
News
Auceliciclib Demonstrates Favorable Safety and Preliminary Activity in Advanced Solid Tumors and Recurrent High-Grade Glioma
03/03/2026
Emily Estrada
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated and demonstrated preliminary disease control with promising safety among heavily pretreated patients with advanced solid tumors and recurrent high-grade glioma.
Auceliciclib was well-tolerated...
03/03/2026
Oncology
News
Dapolsertib Well-Tolerated, Demonstrates Clinical Activity in Acute Myeloid Leukemia
03/02/2026
Emily Estrada
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a manageable safety profile and modest activity among patients with relapsed or refractory AML.
Dapolsertib demonstrated a...
03/02/2026
Oncology
FDA Approval
FDA Approves Zongertinib for HER2-Mutated Metastatic NSCLC
02/26/2026
Emily Estrada
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the Beamion LUNG-1 trial, the FDA has approved zongertinib for patients with HER2-mutated unresectable or metastatic non-squamous non-small cell lung cancer.
Based on results from the...
02/26/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use